Faculty of Medicine
Permanent URI for this communityhttps://repository.ukim.mk/handle/20.500.12188/14
Browse
4 results
Search Results
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, A challenging "silent depth" clinical scenario in North Macedonia: Unmasking a rare case of amelanotic melanoma with trapezius muscle invasion and metastatic disease(Centre for Evaluation in Education and Science (CEON/CEES), 2025); ;Gjorgjeska, Andrijana ;Ivanova, Maja; Aleksovski, DarkoIntroduction: Amelanotic melanoma is a subtype of melanoma that exhibits little or no pigment on visual or histological examination. Approximately 1-8% of all melanomas are amelanotic. It can mimic various benign or malignant melanocytic and non-melanocytic skin tumors, thereby presenting a significant diagnostic challenge. Primary amelanotic melanoma with muscle involvement is an extremely rare entity. A review of the literature revealed no series or case reports. Case Report: We present the case of a 62-yearold female patient with primary amelanotic melanoma infiltrating the trapezius muscle. The tumor was excised together with a clinically positive lymph node on the right side of the neck. Computed tomography (CT) angiography of the lungs, abdomen, and pelvis demonstrated bilateral diffuse nodular changes, a mediastinal pretracheal lymph node, and multiple diffuse liver lesions, consistent with secondary deposits. Molecular pathology revealed positivity for the BRAF V600E2/K/R/D mutation, and the patient began firstline targeted therapy with BRAF/MEK inhibition in accordance with protocols for BRAF-positive metastatic melanoma. Three months later, a follow-up CT scan demonstrated complete remission of the previously observed metastatic changes. Conclusion: Primary amelanotic melanoma with muscle involvement is exceptionally rare, with no published series or case reports identified. This case highlights the importance of early detection and treatment in suspected melanoma and underscores the need to consider melanoma in all clinically unclear cases. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, The advantage of the fixed combinations in patients with glaucoma(Serbian Association of Ophthalmologists, 2018); ; ;Blazevska Buzarovska, Karolina ;Petrusevska, AndrijanaIvanova, Maja - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Treatment of the advanced form of wet macular degeneration with Aflibercept (Eylea) - case report(Здружение на офталмолози на Македонија = Macedonian Association of Ophthalmologists, 2020) ;Ivanova, Maja; ; Velkovska, Bisera - Some of the metrics are blocked by yourconsent settings
Item type:Publication, PROGNOSTIC VALUE OF MOLECULAR MARKER ON OUTCOME IN PATIENTS WITH HIGH-GRADE GLIOMA. SINGLE INSTITUTIONAL EXPERIENCE(Department of Anaesthesia and Reanimation, Faculty of Medicine, “Ss. Cyril and Methodius” University Skopje, R.N.Macedonia, 2020-10); ; ; ;Dzundeva, JasminaIvanova, MajaHigh-grade glioma (HGG) are among the most frequent primary brain tumors. Prognosis in HGG depends on histology, age, performance status, and other patient and tumor related factors. The 2016 revision of the WHO Classification of CNS Tumors introduced molecular characterization of HGG, with possible impact on prognosis. Analysis of a total of 49 patients with HGG with known MGMT methylation status and IDH1 and IDH2 mutation has been done. All patients undergo surgery, followed by concurrent chemoradiotherapy and adjuvant chemotherapy with temozolomide. Median follow up of all patients was 21,3 months (6,2-52,1 months). The Median Disease-free survival (DFS) was 20,3 months, and the median overall survival (OS) was calculated as 21,8 months. Patients has been stratified according to MGMT methylation status and IDH1 and IDH2 mutation status. DFS and OS have been compared between groups. The assessment shows 2-year DFS and OS were 45,5% and 54% for methylated and 40,4% and 47,8 for unmethylated patients. 2-year DFS and OS were 75% and 86% for IDH1 mutated patients and 34,12% and 47,1% for IDH1 unmutated patients. Two-year DFS and OS were 56% and 83% for IDH 2 mutated patients and 28,8% and 40,9% for IDH2 unmutated patients. There were suggestions for favorable prognostic factor for both MGMT methylation and IDH1 and IDH2 mutation, but we did not show any statistically significant difference of DFS and OS between MGMT methylated and unmethylated patients and between IDH1 and IDH2 mutated and unmutated patients due to small specimen and relatively short follow up.
